EPS6.03 Pulmonary pathogen prevalence 12 months after elexacaftor/tezacaftor/ivacaftor introduction: results from the Danish National Cystic Fibrosis Cohort [PDF]
, 2023 M. Jeppesen +9 more
openalex +1 more source
Farmacogenética en Fibrosis Quística. [PDF]
, 2017 La fibrosis quística (a partir de ahora referida como FQ) fue descrita por primera vez en 1936 como una entidad separada. También recibía el nombre de “mucoviscidosis” debido a la acumulación de espesas secreciones mucosas que bloqueaban las vías aéreas,
Oraá Pérez, Javier
core
A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis [PDF]
, 2017 Background: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in patients with cystic fibrosis (CF). Methods: Our treatment-evaluator tool assessed the effectiveness of inhaled aztreonam in routine practice in 117 CF ...
Amadori +36 more
core +1 more source
Health state utility data in Cystic Fibrosis: A systematic review [PDF]
, 2019 Introduction: Cystic fibrosis (CF) is a life-limiting, hereditable condition, with the highest prevalence in Europe. CF treatments have led to improvements in clinical symptoms, disease management and decelerated disease progression.
Archangelidi, Olga +7 more
core +1 more source
MedComm, Volume 7, Issue 1, January 2026.The management of cancer and tissue regeneration remains a substantial challenge to global health. Organoids, which are stem cell‐derived three‐dimensional multicellular structures, are revolutionizing biomedical research. Therefore, this review highlights their applications in cancer research and regenerative medicine, while discussing current ...
Ruiyang Li +5 more
wiley +1 more source
Ivacaftor: A Novel Mutation Modulating Drug [PDF]
Journal of Clinical and Diagnostic Research, 2014 Cystic fibrosis (CF) is multisystemic disorder presenting in newborn period to adulthood, predominantly affecting respiratory system. It is caused by mutation in CF transmembrane conductance regulator gene.
Harit Kapoor, Astha Koolwal, Ankur Singh
doaj +1 more source
Role of the SLC26A9 chloride channel as disease modifier and potential therapeutic target in cystic fibrosis [PDF]
, 2018 The solute carrier family 26, member 9 (SLC26A9) is an epithelial chloride channel that is expressed in several organs affected in patients with cystic fibrosis (CF) including the lungs, the pancreas, and the intestine. Emerging evidence suggests SLC26A9
Balázs, Anita, Mall, Marcus A.
core +1 more source
UK Biobank: Transforming drug discovery and precision medicine
British Journal of Pharmacology, Volume 183, Issue 2, Page 234-248, January 2026.UK Biobank is a large‐scale, prospective study with extensive genetic and phenotypic data on half a million individuals. Volunteers, aged between 40 and 69 years, were recruited between 2006 and 2010 from the general population of the United Kingdom.
Jelena Bešević +11 more
wiley +1 more source
Ivacaftor: Five‐year outcomes in the West of Scotland cystic fibrosis population
The Clinical Respiratory Journal, 2023 Introduction Ivacaftor has shown to be effective in patients with cystic fibrosis (CF) with a G551D mutation. Objectives This work aims to evaluate ivacaftor's effectiveness and safety in the real world, over 5 years, in the West of Scotland CF ...
Yasmin Al‐Din +4 more
doaj +1 more source
ePS6.08 Second-hand smoke exposure reduces the clinical efficacy of ivacaftor in G551D: results from the GOAL study [PDF]
, 2022 S.M. Rowe +4 more
openalex +1 more source